Skip to main content
Manufacturing Facility)

Product Pipeline

Focused on Innovation

CSL Behring is a global leader in developing and delivering high quality medicines that treat people with rare and serious diseases. Working every day as if people’s lives depend on it, CSL’s R&D fuels the company’s sustainable growth by advancing world-class science, technology and collaboration. Our strong R&D pipeline utilises its expertise in plasma fractionation, recombinant technology, and cell and gene therapy to develop and deliver innovative medicines that address unmet medical needs or enhance current treatments in five Therapeutic Areas - Immunology, Hematology, Cardiovascular and Metabolic, Respiratory and Transplant. Our R&D portfolio focuses on innovation in new products, improved products and manufacturing expertise ensuring our continued growth.

Core Capabilities


Research / Pre-Clinical

Clinical Development

Registration / Post-Registration

R&D Portfolio
Phase 2

CSL324 Anti-G-CSFR mAb (HS)

Recombinant monoclonal antibody against the cytokine granulocyte colony stimulating factor receptor for the potential treatment of Hidradenitis Suppurativa.

CSL730 rFc Multimer*

Novel recombinant human Fc multimer for treatment of patients with immune complex-mediated autoimmune diseases.
*Developed in collaboration with Momenta Pharmaceuticals.

HIZENTRA® (SSc)

HIZENTRA®, 20% subcutaneous immunoglobulin, for the treatment of Systemic Sclerosis (SSc).

HIZENTRA® (DM)

HIZENTRA®, 20% subcutaneous immunoglobulin, for the treatment and long-term maintenance therapy of adults with Dermatomyositis (DM).

HAEGARDA® Japan

Self-administered, subcutaneous C1-esterase inhibitor (human) for routine prophylaxis to prevent HAE attacks.

Garadacimab Anti-FXIIa mAb (HAE)

Humanised anti-factor XIIa monoclonal antibody for the potential treatment of Hereditary Angioedema (HAE) by subcutaneous administration.

CSL889 Hemopexin (SCD)

Plasma-derived Hemopexin for the potential treatment of Sickle Cell Disease (SCD).

CSL200 CAL-H (SCD)

Human γ-Globin Gene Therapy for the potential treatment of Severe Sickle Cell Disease (SCD).

CSL630 pdFVIII Ruide

Plasma-derived Human Factor VIII manufactured in China through the acquisition of Wuhan Zhong Yuan Rui De Biological Products Co. Ltd. (Ruide).

EtranaDez (AMT-061; Etranacogene dezaparvovec)*

CSL has entered an agreement with uniQure to acquire exclusive global licence rights to an adeno-associated virus (AAV) gene therapy for the potential treatment of haemophilia B.
*Transaction with uniQure is subject to customary regulatory clearances before closing.

KCENTRA® 4F-PCC (Trauma)

A 4-factor prothrombin complex concentrate (4F-PCC) for the potential treatment of massive hemorrhage associated with severe traumatic injury.

CSL787 Nebulised Ig

Human plasma-derived immunoglobulin for administration via a nebulizer for the potential prevention of chronic respiratory tract infections and progression of chronic lung disease.

CSL311 Anti-Beta Common mAb

Fully human monoclonal antibody inhibiting GM-CSF, IL-3 and IL-5 signalling by neutralising the ß-common receptor for the potential treatment of complex inflammatory diseases.

Garadacimab Anti-FXIIa mAb (ILD/IPF)

A humanised anti-FXIIa monoclonal antibody for the potential treatment of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Diseases (ILD).

CSL346 Anti-VEGFB mAb (DKD)

Humanised monoclonal antibody targeting VEGF-B for the potential treatment of diabetic kidney disease (DKD).

CSL112 ApoA-1 (ACS)

Novel apolipoprotein A-I infusion therapy to potentially reduce the risk of major adverse cardiovascular events (MACE) in patients with Acute Coronary Syndrome (ACS).

Clazakizumab Anti-IL-6 mAb (AMR)

Humanized recombinant monoclonal antibody targeting interleukin-6 (IL-6) for the potential treatment of chronic active antibody-mediated rejection (AMR), the leading cause of long-term rejection in kidney transplant recipients.

CSL964 Alpha-1 Antitrypsin (Treatment of GvHD)*

Treatment of steroid refractory, acute Graft-versus-Host Disease (GvHD) in high-risk patients receiving an allogenic hematopoietic stem cell transplant (HSCT) using Alpha-1 Antitrypsin (AAT).
*In collaboration with Blood and Marrow Transplant Clinical Trials Network (BMT CTN)

CSL964 Alpha-1 Antitrypsin (Prevention of GvHD)

Prevention of acute Graft-versus-Host Disease (GvHD) in high-risk patients receiving an allogenic hematopoietic stem cell transplant (HSCT) using Alpha-1 Antitrypsin (AAT).

UQ/CSL V451 (aCoV2)*

Development and manufacture of a ‘molecular clamp’ enabled vaccine that is combined with proprietary MF59® adjuvant for COVID-19.
*Developed in collaboration with the University of Queensland (UQ) and the Collaboration for Epidemic Preparedness Innovations (CEPI).

Garadacimab Anti-FXIIa mAb (ARDS)

Humanised anti-FXIIa monoclonal antibody for the potential treatment of acute respiratory distress syndrome (ARDS).

COVID-19 Hyperimmune Therapy*

CSL, with Takeda, led the creation of the unprecedented CoVIg-19 Plasma Alliance to accelerate the development of a plasma-derived hyperimmune globulin therapy (CoVIg-19) for the potential treatment of individuals with serious complications of COVID-19.
*Partnered Program

CSL334/ASLAN004 Anti-IL-13R mAb (AD)

Monoclonal antibody targeting IL-13Rα1 for the treatment of atopic dermatitis and asthma.
Licensed to ASLAN Pharmaceuticals.

Mavrilimumab Anti-GM-CSFR mAb

Recombinant monoclonal antibody against the granulocyte macrophage colony-stimulating factor receptor as a potential treatment for inflammatory diseases.
Licensed to Kiniksa Pharmaceuticals.